Friedreich's Ataxia

1. Overview

Friedreich's ataxia (FRDA) is the most common inherited ataxia, affecting approximately 1 in 50,000 people worldwide. It is an autosomal recessive neurodegenerative disease caused by a pathological expansion of a GAA trinucleotide repeat in the first intron of the FXN gene on chromosome 9q21.11, which encodes the mitochondrial protein frataxin. Reduced frataxin levels impair iron-sulfur cluster biogenesis, cause mitochondrial iron overload, and trigger oxidative stress — ultimately destroying large neurons of the dorsal root ganglia and long ascending and descending spinal cord tracts.

The disease typically presents in childhood or early adolescence (mean onset around age 15), although adult-onset forms exist. Progressive cerebellar and sensory ataxia, loss of deep tendon reflexes, and positive Babinski signs are the cardinal neurological features. Critically, Friedreich's ataxia is a multi-system disease: roughly 80% of patients develop hypertrophic cardiomyopathy — the leading cause of premature death — and 10–30% develop diabetes mellitus. Most patients require a wheelchair within about 10 years of symptom onset.

In 2023, the U.S. Food and Drug Administration (FDA) approved omaveloxolone as the first treatment for Friedreich's ataxia. Prior to this, management was entirely supportive.

Back to Table of Contents

2. Epidemiology

Friedreich's ataxia has a prevalence of approximately 1 in 50,000 in populations of European and Middle Eastern ancestry. The estimated carrier frequency is around 1 in 100, making it the most prevalent inherited ataxia in these populations. The disease is considerably rarer in East Asian and sub-Saharan African populations, consistent with the European origin of the ancestral GAA expansion founder haplotype.

Onset typically occurs between ages 5 and 25, with a mean onset of approximately 15 years. Roughly 25% of patients present after age 25 (late-onset Friedreich's ataxia, LOFA), and a very small proportion after age 40 (very-late-onset FRDA, VLOFA). These late-onset forms often show a milder phenotype with slower progression and retained reflexes. Both sexes are equally affected.

The FDA's 2023 approval notice describes Friedreich's ataxia as the most common hereditary ataxia in the United States, affecting about one in every 50,000 people; a 2009 clinical review gives the same rate, about 1 in 50,000, for people of European descent. Because the disease shortens lifespan substantially, point-prevalence figures underrepresent the lifetime burden of the condition.

Back to Table of Contents

3. Genetics and Molecular Mechanism

The FXN gene spans approximately 80 kb on chromosome 9q21.11 and encodes frataxin, a 210-amino-acid mitochondrial protein. The gene contains seven exons; the GAA repeat lies within the first intron between exons 1 and 2. In normal individuals, this intronic GAA repeat is fewer than 40 copies. In Friedreich's ataxia, at least one allele (and typically both) carry expansions of 66 to more than 1,000 repeats.

The expanded GAA repeat adopts an unusual triple-helical DNA structure ("sticky DNA") that impedes transcriptional elongation through the intron, dramatically reducing frataxin mRNA and protein levels. Frataxin expression in affected patients is typically 5–30% of normal. The degree of GAA expansion on the shorter allele correlates inversely with age of onset and disease severity — shorter expansions generally produce milder, later-onset disease.

Approximately 96–98% of FRDA patients are homozygous for GAA expansions. The remaining 2–4% are compound heterozygotes who carry one GAA expansion and one point mutation, missense variant, or deletion in the other FXN allele on the opposite chromosome. The most common point mutation is p.Gly130Val, which confers a milder, slower-progressing phenotype with retained reflexes.

Because the repeat expansion acts by reducing frataxin protein levels rather than producing a toxic gain-of-function protein, strategies that increase frataxin expression — such as gene therapy, epigenetic de-repression, or mRNA stabilization — are actively pursued as therapeutics.

Back to Table of Contents

4. Pathophysiology

Frataxin is a small, highly conserved mitochondrial protein essential for the assembly of iron-sulfur (Fe-S) clusters. These clusters are prosthetic groups required by multiple mitochondrial electron transport chain complexes (I, II, and III) and by the enzyme aconitase in the citric acid cycle. When frataxin is deficient, Fe-S cluster assembly is impaired, and free iron accumulates within the mitochondrial matrix of affected cells.

This mitochondrial iron overload drives the production of highly reactive hydroxyl radicals via the Fenton reaction, causing progressive oxidative damage to mitochondrial DNA, lipids, and proteins. Cells with high metabolic demands and limited regenerative capacity are most vulnerable: the large sensory neurons of the dorsal root ganglia (DRG), neurons of the spinocerebellar tracts, corticospinal tracts, and — outside the nervous system — cardiomyocytes and pancreatic beta cells.

The neurodegeneration in FRDA is characterized by:

• Dorsal root ganglion neuron loss — loss of large myelinated sensory (proprioceptive and vibration) fibers → sensory ataxia and areflexia
• Posterior column degeneration — impaired fine touch, vibration, and proprioceptive signaling
• Spinocerebellar tract degeneration — ataxia of gait and limbs
• Corticospinal tract involvement — upper motor neuron signs (extensor plantar response/Babinski), spastic weakness in later stages
• Clarke's column loss — reduced cerebellar input from the spinal cord

The cerebellum itself is relatively spared early in the disease — distinguishing FRDA from cerebellar ataxias — although dentate nucleus degeneration does occur later. The mixed upper and lower motor neuron picture and prominent sensory loss are hallmarks of the disease.

Back to Table of Contents

5. Clinical Features

The classic presentation of Friedreich's ataxia involves progressive gait and limb ataxia developing in a child or adolescent, accompanied by a constellation of neurological and systemic findings:

Neurological Features

• Gait ataxia — wide-based, unsteady gait; the most common presenting symptom
• Limb ataxia — dysmetria on finger-nose and heel-shin testing
• Areflexia — absent deep tendon reflexes, especially at the knees and ankles (one of the earliest and most consistent findings)
• Positive Babinski sign — extensor plantar response indicating corticospinal tract involvement
• Loss of proprioception and vibration sense — impaired joint position sense; patients often cannot feel a tuning fork at the toes
• Dysarthria — scanning or slurred speech as disease progresses
• Dysphagia — in advanced disease
• Nystagmus and fixation instability — less common than in pure cerebellar ataxias
• Hearing loss — sensorineural, occurs in a minority

Skeletal and Musculoskeletal Features

• Scoliosis — in up to 80% of patients; can be severe and require surgical intervention
• Pes cavus (high-arched feet) — present in the majority; often an early sign before neurological symptoms appear
• Hammer toes
• Muscle weakness — progressive, most marked distally; contributes to foot deformities

Cardiac Features

Hypertrophic cardiomyopathy develops in approximately 80% of patients and is the leading cause of death, accounting for roughly 60% of FRDA fatalities. It typically manifests as concentric left ventricular hypertrophy. Symptoms include exertional dyspnea, palpitations, and syncope. Arrhythmias — including atrial fibrillation, heart block, and ventricular arrhythmias — are common and can cause sudden death. Some patients develop a dilated cardiomyopathy pattern in late disease.

Endocrine Features

Diabetes mellitus occurs in 10–30% of patients (a 2009 clinical review puts it at approximately 10%), caused by frataxin deficiency in pancreatic beta cells impairing insulin secretion. An additional 10–20% have impaired glucose tolerance. Diabetes significantly worsens prognosis and quality of life.

Vision and Optic Nerve

Optic atrophy occurs in approximately 25–30% of patients, often without subjective visual loss in early stages. Visual evoked potentials are frequently abnormal even when clinical vision appears intact.

Back to Table of Contents

6. Diagnosis

The diagnosis of Friedreich's ataxia is confirmed by genetic testing. When a patient presents with progressive ataxia, areflexia, and loss of proprioception in adolescence or early adulthood, molecular testing of the FXN gene is the first step. The usual testing strategy is:

1. Polymerase chain reaction-based sizing of GAA repeats — detects homozygous GAA expansions (the most common genotype, ~97% of FRDA). Normal alleles produce a small polymerase chain reaction (PCR) product; expanded alleles fail to amplify or produce a larger product on triplet-primed polymerase chain reaction.
2. Sequencing of the second allele — if only one expanded allele is found on sizing, the other allele is sequenced to look for point mutations or small deletions.

Supportive investigations include:

• Nerve conduction studies / electromyography (EMG) — typically show absent or markedly reduced sensory nerve action potentials (SNAPs) with preserved motor conduction; consistent with large-fiber sensory neuropathy / ganglionopathy
• Magnetic resonance imaging (MRI) of the spine and brain — reveals cervical and thoracic spinal cord atrophy (especially posterior columns); the cerebellum is relatively preserved early, though dentate nucleus signal changes and mild cerebellar atrophy appear in advanced disease
• Echocardiography — done at diagnosis to look for hypertrophic cardiomyopathy and commonly repeated every year
• Electrocardiogram (ECG) — T-wave inversions and ST-segment changes are common even in asymptomatic patients; arrhythmia monitoring is important
• Glucose tolerance testing / hemoglobin A1c (HbA1c) — used to screen for diabetes at diagnosis and every year
• Visual evoked potentials — assess optic nerve involvement

The Scale for Assessment and Rating of Ataxia (SARA) and the Friedreich's Ataxia Rating Scale (FARS) are validated tools used to track neurological progression in clinical trials and routine care.

International clinical management guidelines for Friedreich ataxia were updated in 2022 using the GRADE method (Grading of Recommendations Assessment and Evaluation). Seventy clinical experts wrote 15 topic chapters with 130 new recommendations and 95 best-practice statements; chapters new since the 2014 edition cover emergency medicine, digital and assistive technologies, and mental health.

Back to Table of Contents

7. Treatment

Disease-Modifying Therapy

In February 2023, the U.S. Food and Drug Administration approved omaveloxolone — the first treatment approved for Friedreich's ataxia. Omaveloxolone is a semisynthetic triterpenoid that activates the Nrf2 (nuclear factor erythroid 2-related factor 2) transcription factor. The U.S. label states that the precise mechanism by which it works in Friedreich's ataxia is unknown; the trial researchers report that, in models of the disease, it improves mitochondrial function, restores redox balance and reduces inflammation. In the MOXIe trial (NCT02255435), a registrational phase 2 trial of 103 people randomized to omaveloxolone 150 mg/day (51) or placebo (52), the pre-planned main analysis covered the 82 participants without pes cavus (a high-arched foot), 40 on the drug and 42 on placebo. In that group the modified Friedreich's Ataxia Rating Scale (mFARS) score improved by 1.55 points with omaveloxolone and worsened by 0.85 points with placebo over 48 weeks, a difference of 2.40 points (p = 0.014). Across all 103 randomized people, pes cavus included, the difference was smaller, 1.93 points (p = 0.034); the label reports it as 1.94 points and calls it nominally significant. It is approved for patients aged 16 years and older.

In a later comparison that was not a randomized trial, 136 people who continued omaveloxolone in the open-label extension were matched with 136 untreated people from a natural-history study. Over 3 years the mFARS score worsened by 3 points with omaveloxolone and by 6.6 points without it (a difference of 3.6 points).

Side effects: the FDA's approval notice lists the most common side effects as raised liver enzymes (alanine aminotransferase and aspartate aminotransferase), which can be signs of liver damage, headache, nausea, abdominal pain, fatigue, diarrhea and musculoskeletal pain. In MOXIe the liver-enzyme rises were temporary and reversible, without a rise in bilirubin or other signs of liver injury. The U.S. label also lists two other warnings: a rise in B-type natriuretic peptide (BNP), a blood marker of heart strain, above 100 pg/mL in 14% of people on the drug against 4% on placebo, where the label states it is unclear whether the rise came from the drug or from the heart disease of Friedreich's ataxia; and a rise in low-density lipoprotein (LDL) cholesterol in 16% on the drug against 8% on placebo. The Omaveloxolone page sets out the trials and the label in detail.

Cardiac Management

Cardiomyopathy management follows standard heart failure guidelines and is the most critical aspect of systemic management:

• Beta-blockers — first-line for symptomatic hypertrophic cardiomyopathy; also reduce arrhythmia risk
• Angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs) — used for patients with reduced ejection fraction or dilated cardiomyopathy
• Antiarrhythmic therapy — rate control or rhythm control for atrial fibrillation; an implantable cardioverter-defibrillator (ICD) is considered for high-risk ventricular arrhythmias
• Annual echocardiography — to monitor left ventricular (LV) wall thickness, ejection fraction (EF), and outflow tract obstruction

Diabetes Management

Diabetes in FRDA is primarily a secretory defect; insulin therapy is often ultimately required. Standard diabetes management protocols apply. Hemoglobin A1c and fasting glucose are commonly checked every year.

Rehabilitative and Symptomatic Therapy

• Physical therapy — core stabilization, balance training, gait aids, fall prevention; delays wheelchair dependence
• Occupational therapy — adaptive devices for activities of daily living; handwriting aids, speech-generating devices
• Speech therapy — dysarthria management; swallowing assessment and modification
• Orthotics and orthopedic surgery — ankle-foot orthoses for foot drop; spinal fusion for severe progressive scoliosis

Investigational Therapies

• Idebenone — a synthetic analog of coenzyme Q10 (CoQ10); showed modest cardiac benefit in early studies but did not reach the primary neurological endpoint in the MICONOS trial; used in some countries off-label. A 2025 review of antioxidant treatments tested in people with Friedreich's ataxia found that only omaveloxolone and, to a lesser extent, idebenone (mainly for heart-muscle thickening) have shown some efficacy
• Gene therapy — adeno-associated virus (AAV)-mediated frataxin delivery to DRG and heart; early-phase trials ongoing (e.g., one run by a gene-therapy developer)
• Epigenetic de-repression — histone deacetylase (HDAC) inhibitors (e.g., nicotinamide, RG2833) aim to reverse GAA repeat-induced chromatin silencing. Nicotinamide is vitamin B3, a cheap vitamin: in a small open-label UK study, daily doses of 3.5–6 g for up to 8 weeks raised frataxin levels significantly and reduced the silencing marks on the FXN gene, but clinical measures of ataxia did not change; nausea was the main side effect
• mRNA therapy — exogenous frataxin mRNA delivery to restore protein levels

Back to Table of Contents

8. Prognosis and Quality of Life

Friedreich's ataxia follows a relentlessly progressive course. The mean time to wheelchair dependence is approximately 10–15 years from symptom onset, though this varies considerably; a 2009 clinical review states that most patients lose the ability to walk, stand or sit without support within 10 to 15 years of onset. Patients with longer GAA repeat expansions and earlier onset generally progress faster. Late-onset FRDA has a more benign trajectory and some patients retain ambulation for decades.

Life expectancy is significantly reduced. Before the era of modern cardiac care, mean survival was approximately 35 years. With active cardiac management — treating arrhythmias, managing cardiomyopathy, and preventing sudden cardiac death — survival has improved substantially. Contemporary data suggest median survival into the mid-40s to early 50s for typical FRDA, with cardiac causes accounting for approximately 59% of deaths in a 2011 US study, non-cardiac causes for 27.9% and unknown causes for 9.8%.

Cognitive function is generally preserved throughout the disease, although mild executive dysfunction and slowed processing speed have been documented. Depression and anxiety are common comorbidities and significantly affect quality of life. The 2022 clinical management guidelines give mental health a chapter of its own; psychological support, peer support networks (such as those run by a patient-advocacy research foundation) and palliative care planning are part of care as the disease advances.

Back to Table of Contents

Key Research Papers

1. Campuzano V, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423–1427. — PubMed PMID: 8596916
2. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256(Suppl 1):3–8. — PubMed PMID: 19283344
3. Tsou AY, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1–2):46–49. — PubMed PMID: 21652007
4. Strawser C, et al. Pharmacological therapeutics in Friedreich ataxia: the present state. Expert Rev Neurother. 2017;17(9):895–907. — PubMed PMID: 28724340
5. Lynch DR, Chin MP, Delatycki MB, et al. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021;89(2):212–225. — PubMed PMID: 33068037
6. Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013;72(2):78–90. — PubMed PMID: 23334592
7. Bürk K. Friedreich Ataxia: current status and future prospects. Cerebellum Ataxias. 2017;4:4. — PubMed PMID: 28405347
8. Rötig A, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17(2):215–217. — PubMed PMID: 9326946
9. Pousset F, et al. A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich ataxia. JAMA Neurol. 2015;72(11):1334–1341. — PubMed PMID: 26414159
10. Parkinson MH, et al. Clinical features of Friedreich's ataxia: classical and atypical phenotypes. J Neurochem. 2013;126(Suppl 1):103–117. — PubMed PMID: 23859346
11. Delatycki MB, Bidichandani SI. Friedreich ataxia — pathogenesis and implications for therapies. Neurobiol Dis. 2019;132:104606. — PubMed PMID: 31494282
12. Schmucker S, Puccio H. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. Hum Mol Genet. 2010;19(R1):R103–110. — PubMed PMID: 20413654
13. Lynch DR, Goldsberry A, Rummey C, et al. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Ann Clin Transl Neurol. 2024;11(1):4–16. — PubMed PMID: 37691319
14. Corben LA, Collins V, Milne S, et al. Clinical management guidelines for Friedreich ataxia: best practice in rare diseases. Orphanet J Rare Dis. 2022;17(1):415. — PubMed PMID: 36371255
15. Libri V, Yandim C, Athanasopoulos S, et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet. 2014;384(9942):504–513. — PubMed PMID: 24794816
16. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, et al. Oxidative Stress and Antioxidant Therapies in Friedreich's Ataxia. Cells. 2025;14(18):1406. — PubMed PMID: 41002373
17. U.S. Food and Drug Administration. FDA approves first treatment for Friedreich's ataxia. 28 February 2023. — fda.gov

1. PubMed: Topic search: Friedreich ataxia frataxin
2. PubMed: Topic search: Friedreich ataxia omaveloxolone treatment
3. PubMed: Topic search: Friedreich ataxia cardiomyopathy

Back to Table of Contents

Connections

• Neurology
• Cerebellar Ataxia
• Omaveloxolone
• Peripheral Neuropathy
• Cardiomyopathy
• Diabetes
• Multiple Sclerosis
• Parkinson's Disease
• Huntington's Disease
• Amyotrophic Lateral Sclerosis
• Iron
• Vitamin E
• Oxidative Stress
• Scoliosis

Back to Table of Contents

×

Featured Videos